US23255M2044 - Common Stock
CYCLERION THERAPEUTICS INC
NASDAQ:CYCN (4/25/2024, 3:30:01 PM)
3.04
+0.27 (+9.75%)
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 16 full-time employees. The company went IPO on 2019-03-18. Its portfolio includes novel soluble guanylate cyclase (sGC) stimulators that modulate a key node in a fundamental signaling network in both the central nervous system (CNS) and the periphery. Zagociguat is a clinical-stage CNS-penetrant sGC stimulator that has shown rapid improvement in cerebral blood flow, functional brain connectivity, brain response to visual stimulus, cognitive performance, and biomarkers associated mitochondrial function and inflammation in clinical studies. CY 3018 is a CNS-targeted sGC stimulator that preferentially localizes to the brain and has a pharmacology profile that suggests its potential for the treatment of neuropsychiatric diseases and disorders. Praliciguat is a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. and being advanced in rare kidney disease. Olinciguat is a vascular sGC stimulator that the Company intends to out-license for cardiovascular diseases.
CYCLERION THERAPEUTICS INC
301 Binney Street
Cambridge MASSACHUSETTS 02142
P: 16176217722
CEO: Peter M. Hecht
Employees: 16
Website: https://www.cyclerion.com/
Cyclerion Therapeutics just reported results for the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cyclerion Therapeutics (NASDAQ:CYCN) just reported results for the fourth quart...
– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep...
- Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurological and psychiatric disorders
Here you can normally see the latest stock twits on CYCN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: